Swedish Orphan Biovitrum AB (LTS:0MTD) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 16, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

As of today (2024-05-16), Swedish Orphan Biovitrum AB's Predictability Rank is 2.5-Stars. Swedish Orphan Biovitrum AB's intrinsic value calculated from the Discounted Dividend model is kr105.08 and current share price is kr288.40. Consequently,

Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based) using Discounted Dividend model is N/A.

Competitive Comparison of Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based)

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based) falls into.

Swedish Orphan Biovitrum AB Margin of Safety % (DCF Dividends Based) Calculation

Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based) for today is calculated as

Margin of Safety % (DCF Dividends Based)	=	(Intrinsic Value: DCF (Dividends Based)	-	Current Price)	/	Intrinsic Value: DCF (Dividends Based)
	=	(0.00	-	288.40)	/	0.00
	=	N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Dividend model with default parameters.

Swedish Orphan Biovitrum AB Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (LTS:0MTD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (LTS:0MTD) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

SWOBY:USA BIOVF:USA SOBI:Sweden SOBIs:UK B6E:Germany B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Swedish Orphan Biovitrum AB (LTS:0MTD) Headlines

No Headlines